EnteroMedics Appoints CEO
This article was originally published in Scrip
Executive Summary
EnteroMedics Inc., a company developing medical devices, has appointed Dan Gladney president and CEO – effective Nov. 16, 2015. Gladney has also been appointed to the company's board. Current president, CEO and chair of EnteroMedics, Mark Knudson, will remain its executive chair until the beginning of 2016, when he will become non-executive chair of the company's board. Most recently Gladney was director and CEO of Lanx Inc., a medical device company, which was later acquired by Biomet Inc. Prior to Lanx, Gladney was healthcare operating partner at Norwest Equity Partners and prior to this, he was president and CEO of various companies including Heart Leaflet Technologies and ACIST Medical Systems, both of which were acquired by The Bracco Group.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.